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Sander Ouburg2, Lodewijk Spanjaard6, Servaas A Morré2,7 and A Marceline van Furth1Abstract
Background: Sensorineural hearing loss is the most common sequela in survivors of bacterial meningitis (BM). In
the past we developed a validated prediction model to identify children at risk for post-meningitis hearing loss. It is
known that host genetic variations, besides clinical factors, contribute to severity and outcome of BM. In this study
it was determined whether host genetic risk factors improve the predictive abilities of an existing model regarding
hearing loss after childhood BM.
Methods: Four hundred and seventy-one Dutch Caucasian childhood BM were genotyped for 11 single nucleotide
polymorphisms (SNPs) in seven different genes involved in pathogen recognition. Genetic data were added to the
original clinical prediction model and performance of new models was compared to the original model by
likelihood ratio tests and the area under the curve (AUC) of the receiver operating characteristic curves.
Results: Addition of TLR9-1237 SNPs and the combination of TLR2 + 2477 and TLR4 + 896 SNPs improved the
clinical prediction model, but not significantly (increase of AUC’s from 0.856 to 0.861 and from 0.856 to 0.875
(p = 0.570 and 0.335, respectively). Other SNPs analysed were not linked to hearing loss.
Conclusions: Although addition of genetic risk factors did not significantly improve the clinical prediction model
for post-meningitis hearing loss, AUC’s of the pre-existing model remain high after addition of genetic factors.
Future studies should evaluate whether more combinations of SNPs in larger cohorts has an additional value to the
existing prediction model for post meningitis hearing loss.
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Bacterial meningitis (BM) is the leading cause of ac-
quired hearing impairment in children [1]. The reported
overall incidence of sensorineural hearing loss (HL) in
children surviving BM ranges from 7-36% [2-5]. It is
thought that the large differences in reported incidences
is explained by underestimation in some studies due to
the difficulties in detecting HL. Because in mostly audio-
metric testing is only performed in clinical suspected* Correspondence: r.c.j.dejonge@erasmusmc.nl
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reproduction in any medium, provided the orcases of HL, many cases are late or never diagnosed [5].
Especially in children, early identification and rehabilita-
tion of HL is indispensable because even mild changes
in hearing abilities may impair auditory, linguistic, com-
munication and learning skills with life-long conse-
quences. For that reason, routine hearing evaluation is
recommended in the standard follow-up program of
childhood BM aiming to achieve more timely interven-
tion [6]. To support the recognition of patients at high
risk for HL after BM, Koomen et al. developed a clinical
prediction model based on five predictors, including: dur-
ation of symptoms prior to admission longer than two
days, the absence of petechiae, cerebrospinal fluid (CSF)
glucose level ≤0.6 mmol/L, Streptococcus pneumoniae as
causative pathogen and the presence of ataxia during thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identified in an early stage of the disease. It was recently
successfully validated in an independent validation cohort
of childhood BM survivors [7]. Besides clinical, environ-
mental and pathogen-related factors, the ability of the
host’s innate immune system to clear bacterial infections
also influences the course of BM. In meningitis caused by
Neisseria meningitidis or S. pneumoniae, host genetic fac-
tors are shown to play an important role [8,9]. Single nu-
cleotide polymorphisms (SNPs) in genes encoding for
receptors involved in recognition of S. pneumoniae and
N. meningitidis are associated with severity of both men-
ingococcal and pneumococcal infections [10,11]. Mice
studies have shown that Toll-like receptor (TLR) mediated
signaling is important in the initiation of the inflammatory
response in the central nervous system (CNS) during pneu-
mococcal meningitis [12,13]. This is also shown in the
cochlea, since in this same animal model TLR-associated
adapter molecule Myd88 knockout mice developed signifi-
cantly less HL and had diminished cochlear inflammation
compared to wild type mice [14]. There is increasing evi-
dence that TLRs contribute to cochlear damage in menin-
gitis [15]. We recently found an association of SNPs in
TLR-2, -4 and −9, with an increased risk of HL in survivors
of childhood BM suggesting that SNPs in TLRs and other
peptides involved in pathogen recognition may be valu-
able markers to predict the individual risk to develop post-
meningitis HL [16].
The aim of this study was to determine whether ad-
dition of host genetic risk factors in the pathogen recog-
nition system could improve the prediction model of
post-BM HL compared to the prediction model using
clinical risk factors alone in children with pneumococcal
and meningococcal meningitis.
Methods
Study population and collection of clinical data
The cohort used in this study is composed of two inde-
pendent, comparable cohorts of school-age BM survi-
vors: a development cohort and a validation cohort, both
described in detail in the original studies [3,7]. In short,
patients and data in both cohorts were retrospectively
selected from data on bacterial cerebrospinal fluid (CSF)
isolates of the Netherlands Reference Laboratory for
Bacterial Meningitis (NRLBM) of patients treated in 110
different Dutch hospitals. The NRLBM receives approxi-
mately 90% of the isolates of Dutch meningitis patients
[17]. The diagnosis meningitis was based on the demon-
stration of pathogens or antigens of S. pneumoniae or N.
meningitidis in the CSF by culture or latex agglutination
respectively. Children with “complex onset” of meningitis
(defined as meningitis secondary to immune deficiency
states, cranial trauma, CNS surgery, and CSF shunt infec-
tions) or relapsing meningitis were excluded.For construction of the development cohort, files of
the NRLBM were searched for children born between
January 1986 and December 1994 who survived BM be-
tween January 1990 and December 1995. Sixteen hun-
dred and five children were eligible for inclusion and
their pediatricians were approached to send the parents
a letter requesting participation. Six hundred and twenty-
eight were included, and their medical records were inves-
tigated for risk factors and for perceptive HL of >25 dB.
After internal validation this model was transformed into
a clinical prediction rule including the variables: duration
of symptoms prior to admission longer than two days,
the absence of petechiae, CSF glucose level ≤0.6 mmol/L,
S. pneumoniae as causative pathogen and the presence of
ataxia during the illness. With this rule, a total risk score
was calculated for each patient. The risk scores and the
matching probability of HL were visually presented in a
nomogram for use in clinical practice [3].
The clinical prediction rule was successfully validated
in the validation cohort consisting of 116 children. The
cohort was constructed in 2005 from files of the
NRLBM and consisted of children born between January
1993 and December 1999 who suffered from non-Hib
BM between January 1997 and December 2001 (unpub-
lished observations, de Jonge et al.).
For the present study, all Dutch-Caucasian survivors
of BM caused by S. pneumoniae or N. meningitidis were
selected from the combined development and validation
cohorts. Parents (or guardians) of the patients were
asked by mail to participate in the study and to return a
sterile swab after collecting buccal DNA of the children.
Genetic data for our study were collected in the period
from 2006 till 2010. The Medical Ethical Committee of
the VU University Medical Center approved this study.
Information on HL was retrieved from medical records
after parents’ permission. The outcome measure HL was
defined as unilateral or bilateral perceptive loss of >25 dB
and was based on findings in these records and on par-
ental information provided in the questionnaires about
the children’s health (Dutch versions of the CHQ and
the HUI mark 2&3 [18,19]). Conductive HL was not
included.
Information on hearing loss was also collected by re-
viewing medical records kept by the pediatrician and the
otolaryngologist during admission and during follow-up.DNA isolation
DNA was isolated from the buccal swabs using the
following procedure: after addition of 250 μl 10 mM
Tris–HCl (pH 7.4) the sample was heated at 96 degrees
Celsius for 10 minutes. After mixing for 10 seconds the
swabs were removed and the sample was centrifuged
(14,000 rpm).
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Genotyped SNPs include TLR2-16934 T > A (NCBI SNP
CLUSTER ID: rs4696480),TLR2 + 2477 G >A (rs5743708),
TLR4 + 896 A >G (rs4986790), TLR9 -1237 T >C (rs574
3836) and TLR9 +2848 G >A (rs352140), nucleotide oligo-
merisation domain protein (NOD)-1 + 32556 (T- >GG)
(rs6958571), NOD2 + 2209 C > T (rs2066844), NOD2 + 27
22 G >C (rs2066845), NOD2 + 3020 ins C (rs5743293),
Caspase (CASP)-1 + 8404 A >G (rs2282659), and tumour
necrosis factor-related apoptosis inducing ligand (TRAIL)-
692 T >C (rs365238). Results of a selection of these SNPs
were described before in previous studies in 393 patients
[16]. DNA was genotyped by real-time PCR using the
TaqMan AbiPrism® 7000 Sequence Detection System (Ap-
plied Biosystems, UK) with the standard TaqMan protocol
and the LightCycler® 480 System (Roche Applied Science,
US). Results were analyzed by two independent researchers.
SNPs within the same gene or in the same biological
pathway that showed a significant or trend association
with the outcome measure HL in univariable analysis
were combined (described in detail later). Studied com-
binations of SNPs were: TLR2-16934, TLR2 + 2477, and
TLR4 + 896 (stimulating MyD88 via TIRAP and triggering
the intracellular signaling cascade), TLR4 + 896, TLR9-
1237 and TLR9 + 2848 (activating the MyD88 pathway)
and the three NOD2 SNPs (+2209, +2722 and +3020)
[20]. TLR9 haplotypes were determined by genotyping of
both TLR9-1237 T > C and TLR9 + 2848 G >A, which al-
lows 4 locus haplotypes to be distinguished, as described
by Lazarus et al. [21].
Statistics
Genetic variables were coded as categorical variables with
the following assigned categories in single gene analysis:
“0” = no mutant alleles, “1” = one mutant allele, “2” = two
mutant alleles. In children with- and without HL the
distributions of all 11 SNPs and TLR9 haplotypes were
compared. Univariable analysis was performed to explore
associations of genetic variables with the outcome measure
HL by χ2 tests. Fisher’s Exact test was used if the data did
not meet the criteria for a valid χ2-test. SNPs that showed
a significant association (p < 0.05)with HL were further ex-
plored to see whether combined carriage of two or more
specific SNPs resulted in more significant associations.
Combined genes were coded as categorical variables by
specific codes: “0” = no mutant alleles in both genes, “1”
and “2” = one of both specific mutant allele in both genes
“3” = four mutant alleles in both genes. Statistical signifi-
cance was considered with 2-tailed p-values of <0.05.
To investigate whether genetic single and combined
variables were able to improve the predictive ability of
the clinical model we separately selected the most im-
portant genetic predictors for HL by using the least ab-
solute shrinkage and selection operator (Lasso) method[22]. This is a statistical method to reliably select variables
when there are more variables compared to the outcome
categories (also called the events per variable problem)
[23]. In a subsequent step the incremental predictive value
of the most important genetic variables selected with the
lasso method was assessed. Each important genetic vari-
able was added to the clinical prediction model and the
log likelihood values of the models with and without the
genetic variable were compared and tested for significance
conducting likelihood ratio tests [22]. Furthermore, the
discriminative ability was compared based on the AUC of
the ROC [22,24]. AUC’s of the models were obtained and
tested for significant differences by using bootstrapping
techniques [25]. We also used reclassification tables to as-
sess if subjects were reclassified to appropriate risk cat-
egories if genetic variables were added to the model. For
this purpose the Net Reclassification Index (NRI) was cal-
culated for different probability values of HL (ranging
from 10% to 90%) [22,26].
Patients with missing data in one of the five predictors
or SNPs were excluded from analysis. SNPs that could
not be genotyped after 3 real-time PCR assays were also
excluded from analysis.
For statistical analysis, SPSS Statistics 17.0 (IBM Cor-
poration, Somers, NY) and R (The R Project for Statis-
tical Computing) were used.
Results
Participants
After exclusion of the cases of meningitis caused by
pathogens other than N. meningitidis and S. pneumoniae
and non-Dutch-Caucasians from both cohorts, 669 pa-
tients were eligible. They were invited to participate in
the study. A total of 471 (70%) returned an intact buccal
swab and an informed consent form. Reasons why pa-
tients were not included were: refusal to participate
(6%), no response (20%) and damage to the swabs during
mail delivery (4%). Our cohort consisted of 391 menin-
gococcal meningitis (MM) patients and 80 pneumococ-
cal meningitis (PM) patients (n = 395 children from the
development cohort and 76 children from the validation
cohort).The mean age of the patients at infection was
2.6 years (range 0 – 9). Forty-five percent of the children
were female and 55% were male. There was no signifi-
cant difference in distribution of the five predictors of
the prediction rule or SNP distribution between both co-
horts. Table 1 provides an overview of patient charac
teristics and included clinical variables of the original
model.
Genetic analysis
Table 2 provides an overview of genotype distributions
of SNPs used in this study. A selection of these SNP dis-
tributions were described in previous studies [16,27,28].
Table 1 Patients and clinical variables
Characteristics Study cohort n = 471
Total (% missing) Cases (n) (%)
General characteristics
Male gender a 471 (0) 260 55.2%
Outcome measure
Hearing loss a 471 (0) 34 7.2%
Clinical predictors
Duration of symptoms > 2 daysa 464 (1.5) 110 23.7%
Petechiae a 463 (1.7) 273 59.0%
CSF glucose≤ 0.6 mmol/l a 418 (11.2) 125 29.9%
Causative pathogen in CSF: 471 (0)
N. meningitidis a 391 83%
S. pneumoniae a 80 17%
(transient) ataxia a. b 471 (0) 16 3.4%
a Number of subjects (%).
b (Transient) ataxia was defined as signs of ataxia, which lasted at least until
discharge from the hospital, as documented in the medical records.
Abbreviations:
No.: Number.
CSF: Cerebrospinal fluid.
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Percentage of missing data in genetic variables ranged
from 0.8% in CASP1 + 8404 up to 5.9% in TLR2-16934.
Percentage of missing data in clinical risk factors were
0% in “causing pathogen” and “ataxia”, 1.5% in “duration
of symptoms > 2 days”, 1.7% in “petechiae” and highest
in “CSF glucose” (11.3%). Patients with missing data were
excluded from the models. This resulted in 14% missing
cases in the clinical model and 28% of missing cases dur-
ing the selection of genetic variables.
Selection of genes by Lasso
The most important genetic variables selected by the Lasso
method (and coefficients) were: TLR4 recessive alleles (co-
efficient −0.031), TLR9-1237 dominant alleles (coefficient
0.372) and NOD2SNP13 dominant alleles (coefficient 0.183)
in the single gene analysis. Combinations of TLR2 + 2477
and TLR4 (coefficient 1.053),TLR2-19634 and TLR4 (coeffi-
cient 0.124), TLR2 + 2477 and TLR9 + 2848 (coefficient
0.974) were all included in the analysis.
Addition of SNPs to the clinical prediction model
Results of the performance of the original clinical predic-
tion model compared with that of different models ex-
tended with genetic variables selected by the lasso method
are presented in Table 3. Likelihood ratio tests were
performed to test the goodness of fit between the two
models. The AUC curve of the original clinical model was
0.856. Addition of TLR4 SNPs to the clinical model
resulted in a slightly decreased AUC. Addition of TLR9-
1237 to the clinical model slightly increased the AUCcurve to 0.861, though this was not significant (p = 0.570).
NOD2 SNPs did not improve the clinical model.
The AUC was 0.875 after addition of the combination
of TLR2 +2477 and TLR4 SNPs to the clinical model,
which was not significant (p = 0.335). This was also ob-
served after addition of TLR2-16934 and TLR4 (AUC
0.869, p = 0.377). Addition of neither the combination of
TLR2 + 2477 and TLR9 + 2848, nor TLR9 genotypes did
not significantly improve the AUC the model (results
not shown).
Figure 1 shows the AUC’s of the ROC’s of the original
model compared to those of the new models including
genetic variables that showed an increase in AUC.
Results of reclassification tables showed that addition
of SNPs by different probabilities of HL did not improve
the detection of cases and non-cases (data not shown).
Discussion
In this study we determined whether host genetic risk
factors improve the predictive abilities of an existing
model regarding HL after BM in childhood. Although in
univariable analysis TLR SNPs were significantly associ-
ated with HL [16], addition of these high risk genes did
notresult in a significant improvement of a clinical pre-
diction model for HL after BM.Using reclassification ta-
bles, a new technique for assessing the performance of
prediction models, no improvement of the model was
observed, conform the results of the AUC’s.
In order to explain mechanisms that may underlie the
role of TLRs in post-meningitis HL, we focus on patho-
genesis of meningitis. Bacteria spread from the subarach-
noid space to the inner ear through the cochlear aqueduct,
along the eighth nerve or the blood vessels of the blood-
labyrinth barrier [15], inducing a suppurative labyrinthitis.
As a result, the blood-labyrinth barrier and hair cells are
damaged and neurons in the spiral ganglion show apop-
tosis. In the inner ear, bacteria multiply uncontrolled and
after autolysis bacterial components are released, binding
to pathogen recognition receptors (PRRs) present on im-
munocompetent endothelial cells and fibrocytes [29]. PRRs
initiate the immune response and stimulate production of
cytokines. There is increasing evidence for a role of TLRs
in mediating cochlear damage in meningitis [15].
In general, a prediction model is interpreted to be excel-
lent, good, or fair, when its AUC is 0.9 to 1.0, 0.8 to 0.9, or
0.7 to 0.8, respectively. The AUC of the clinical model was
0.856, thus it can be considered as a good model. Improv-
ing a model that is already considered as good, is difficult
because only very strong predictors may result in a signifi-
cant improvement, while other moderately strong predic-
tors do not affect the model [30].
Our results are consistent with findings of other stud-
ies. Clinical factors, in contrast to genetic factors are fre-
quently included in clinical prediction models for other
Table 2 Genotype distributions of SNPs used in this study
Genetic variables Total * Wildtype Heterozygous Mutant
N % N % n % n %
TLR2-16934 T > A HL 32 94.1 7 21.9 15 46.9 10 31.3
TLR2-16934 T > A no HL 411 94.1 114 27.7 196 47.7 101 24.6
TLR2 + 2477 G > A HL 34 100 34 100 0 0 0 0
TLR2 + 2477 G > A no HL 430 98.4 382 88.8 46 10.7 2 0,5
TLR4 + 896 A > G HL 34 100 25 73.5 8 23.5 1 2.9
TLR4 + 896 A > G no HL 420 96.1 374 89.0 33 7.9 13 3.1
TLR9-1237 T > C HL 33 97.1 21 63.6 12 36.4 0 0
TLR9-1237 T > C no HL 430 98.4 320 74.4 101 23.5 9 2.1
TLR9 + 2848 G > A HL 33 97.1 5 15.2 16 48.5 12 36.4
TLR9 + 2848 G > A no HL 426 97.5 104 24.4 199 46.7 123 28.9
NOD1 + 32556 T > GG HL 34 100 20 58.8 13 38.2 1 2.9
NOD1 + 32556 T > GG no HL 414 94.7 239 57.7 148 35.7 27 6.5
NOD2 +2209 C > T HL 34 100 32 94.1 2 5.9 0 0
NOD2 +2209 C > T no HL 427 97.7 381 89.2 38 8.9 8 1.9
NOD2 +2722 G > C HL 31 91.2 31 100 0 0 0 0
NOD2 +2722 G > C no HL 421 96.3 410 97.4 8 1.9 3 0.7
NOD2 +3020 ins C HL 33 97.1 31 93.9 2 6.1 0 0
NOD2 +3020 ins C no HL 426 97.5 409 96.0 16 3.8 1 0.2
CASP1 + 8404 A > G HL 34 100 22 64.7 10 29.4 2 5.9
CASP1 + 8404 A > G no HL 433 99.11 258 59.6 145 33.5 30 6.9
TRAIL-692 T > C HL 33 97.1 26 78.8 6 18.2 1 3.0
TRAIL-692 T > C no HL 420 96.1 339 80.7 72 17.1 9 2.1
*Genotypes and percentage of all included cases.
Abbreviations:
TLR: Toll-like receptor.
HL: Hearing loss.
NOD: Nucleotide oligomerization domain protein.
CASP: Caspase.
TRAIL: Tumour necrosis factor related apoptosis inducing ligand.
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gated the predictive ability of genetic models in type II
diabetes [31]. Almost without exception, the genetic risk
models (including 18–40 SNPs) had lower AUC values
than the clinical models. AUC values from genetic
models ranged from 0.55 to 0.68 and those from clinical
models from 0.61 to 0.92. Moreover, addition of genetic
factors showed no or only marginally improved AUC be-
yond that of clinical risk models [31]. Recently two studies
on predictive ability of SNPs in inflammatory diseases
were published. In one study, addition of genetic risk fac-
tors to clinical predictors did not improve the prediction
of risk of rheumatoid arthritis [32]. In another study, pre-
dictability of three knee osteoarthritis genes was poor
(AUC 0.55 compared to 0.68 for clinical data only), but
likelihood ratio improved slightly (AUC 0.69) by combin-
ing genes with clinical data. After age adjustment of con-
trols, the combined AUC increased to 0.74 [33]. It should
be mentioned that design and population characteristicswere found to importantly affect the observed predictive
performance of risk models [31,34]. In general and by def-
inition, the predictive ability of risk models is higher when
there are larger differences between cases and controls on
the risk factors included in the risk model. In our study,
population characteristics that may have negatively in-
fluenced the predictability of the model included age, sex
and causative pathogen since these factors contribute to
heterogeneity between groups which may differentially
affect the outcome HL. The number of cases of HL was
too small to divide our population in specific subgroups.
Inclusion of a larger number of patients prospectively
would enable to make these selections.
Although limited in the way mentioned above, we be-
lieve this study has some strengths. To our knowledge,
the role of genetic pre-disposition to post-meningitis HL
has only once been publicized earlier in a letter including
5 patients [35]. We are the first testing this hypothesis in a
large patient group using very recently identified relevant
Table 3 Results of the performance of the original clinical
model compared with that of different models extended
with genetic variables selected by the lasso method
SNP / SNP
combination
Log
likelihood
values
AUC of
ROC
95% CI of
AUC of ROC
p-valuea
Clinical model 0.856 0.794-0.909
TLR4 0.2802 0.854 0.786-0.911 0.780
TLR9-1237 −0.5675 0.861 0.798-0.915 0.570
NOD2-SNP13 0.8338 0.855 0.796-0.908 0.404
TLR2+ 2477 and TLR4 −0.9646 0.875 0.816-0.925 0.335
TLR2-19634 and TLR4 −0.8836 0.869 0.812-0.920 0.377
TLR2+ 2477 and
TLR9+ 2848
0.0843 0.855 0.780-0.918 0.933
a AUC combined SNP model versus clinical model.
Abbreviations:
SNP: Single nucleotide polymorphism.
AUC: Area Under the Curve.
ROC: Receiver Operator Curve.
95% CI: 95% confidence interval.
TLR: Toll-like receptor.
NOD: Nucleotide Oligomerization Domain protein.
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since is it an upcoming, promising technique which may
be of clinical relevance in the future [22,24]. For valid in-
terpretation of genetic prediction studies it is crucial to
optimize the quality of the reporting of these studies. In
order to strengthen the reporting of Genetic Risk Predic-
tion studies (GRIPS), a multidisciplinary workshop spon-
sored by the Human Genome Epidemiology Network
developed a checklist of 25 items recommended [34]. Our
study meets all these 25 items, pursuing a new standard of
quality in genetic risk prediction research. We subscribe
the vision of Goldstein that attention should shift from
searching for common variants by genome scans of ever
larger samples to studies of rare variants with a largerFigure 1 ROC curves before and after addition of genetic variants tha
line: ROC curve of the original model (AUC 0.856). Red line: ROC curve of t
original model (AUC 0.861). B. Addition of the combination of TLR2 + 2477
combination of TLR2-16934 and TLR4 SNPs to the original model (AUC 0.86effect [36]. Using a candidate gene approach allows us to
identify such genes with potential relevance in prediction.
It depends on the field of interest and the outcome
measure whether biomarkers like SNPs have an additive
value. For instance, for decision making in an emergency
room only clinical predictors and biomarkers that are
part of routine care and are easily available are useful.
Though in oncology, where prognosis and decisions on
therapy are often more a matter of days or weeks, genetic
factors can be of great value. Currently, genetic factor ana-
lysis seems not contributory in the clinical context of BM.
But, we are convinced that the concept of addition of gen-
etic factors to clinical prediction rules is an interesting
concept. Genetic risk factors will play an increasing key
role in understanding pathophysiology of disease and out-
come, and will become rapidly cheaper and faster avail-
able. To find the genetic factors with strongest predictive
value new techniques like next-generation sequencing and
genome-wide association studies (GWAS) can be used
next to the candidate gene approach. Sequentially, the
found genetic risk factors must be implemented in the de-
velopment process of clinical prediction models to avoid
the aforementioned problem difficult improvement of al-
ready strong models.
This study shows us the direction that studies includ-
ing genetic predictors should be going. In order to use
genetic factors in clinical practice several steps have to
be taken. Our group is planning to develop a prediction
model including both genetic and clinical data from the
commencement of the study. It is more likely that genetic
factors help to amend less robust prediction models requir-
ing improvement. Other components of signal transduction
routes of TLRs may be important in the pathogenesis of
BM e.g. complement genes, signal transduction genes such
as Toll/interleukin-1 receptor domain-containing adaptor
protein (TIRAP) and cytokine genes. Inclusion of theset showed an improvement compared to the original model. Black
he original model including SNPs. A. Addition of TLR9-1237 to the
and TLR4 SNPs to the original model (AUC 0.875). C. Addition of the
9).
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the predictive abilities of new prediction models. Taken
together, this will most likely lead to optimizing personal-
ized public health programs and identification of high risk
groups [37]. Complementary, health protection, fueled by
genetic risk profiles will be a highly effective and efficient
public health task [38]. In general, the success rate of timely
translation of genome-based technologies to commercially
feasible products or services with applicability in health care
systems is significantly low. Lal et al. developed a new
model of valorization to optimize integration of genome-
based technologies into the healthcare system [39].
Another new method for early prediction of post men-
ingitis hearing loss is the Gadolinium-enhanced MRI,
reaching a sensitivity to 100% [40]. Since MRI is an ex-
pensive diagnostic tool, good prediction rules may help
to select those children who need to undergo an MRI
screening.
For further interpretation of the results of this study
and more specific recommendations with regard to gen-
etic predictors in meningitis, it is necessary to address our
limitations. A disadvantage of using buccal DNA, which is
taken by patients or parents themselves, is the potential
poor quality of certain parts of DNA. For that reason,
SNPs that could not be genotyped after 3 real-time PCR
essays were excluded from analysis. We used a retrospec-
tive dataset which may induce selection bias and missing
data. The definition of the outcome was based on docu-
mentation in patient records, and not based on a stan-
dardized protocol for HL. Further, the incidence of HL
may be underestimated and the degree of hearing impair-
ment is reported to be fluctuating [5,41]. Later deterioration
of hearing in time after an initial absence of problems
might occur. Last, we developed and validated the predic-
tion model in a broad population with most possible path-
ogens included. It is known, and logically also found by
the model, that HL is most common in pneumococcal
BM. In our population the most common pathogen is
N. menigitidis. With all changes in the distribution of
responsible pathogens in recent years, due to vaccination
programs and spontaneous decrease in incidence, it is rea-
sonable to think the performance of the model changes in
the nowadays situation. This again supports the need for
continuing validation and redevelopment if necessary.
Conclusion
We conclude that genetic factors did not increase the
ability of the existing clinical model to predict the risk of
post-meningitis HL significantly. Nevertheless, our study
is new in showing the first results of the potential to
combine genetic with clinical risk factors in BM. Know-
ledge about genetic risk factors may be used to target
diagnostic, preventive, and therapeutic interventions for
complex disorders based on a person’s genetic risk, or tocomplement existing risk models based on non-genetic
factors [34]. Additional research including genetic vari-
ables from the commencement of the study, enforced by
current technical advances in SNP detection is crucial to
develop robust prediction rules ready for clinical practice.
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